(Reuters) – Eli Lilly and Co will not seek approval for one of its most promising experimental drugs for treating breast cancer after it failed in a late-stage trial, denting investor hopes for one of…
eli lilly
An Experimental Lilly Cancer Drug Misses A Lucrative Target
In a setback to Eli Lilly, a late-stage study found that a closely watched experimental drug failed to meet its primary endpoint in combating breast cancer. Although expectations on Wall Street had al…
In another stinging setback, Eli Lilly’s ramucirumab fails PhIII breast cancer study
The crucial late-stage failure–ramucirumab for breast cancer has been considered one of the pharma giant’s top Phase III prospects–scuttles one of Eli Lilly’s chief hopes for a major new drug approv…
Lilly’s drug meets goals for gastric cancer treatment, fails in breast cancer trial
Sept 26 (Reuters) – Eli Lilly and Co said its experimental cancer drug failed to improve the survival among breast cancer patients without their cancer worsening in a late-stage trial. However, a sep…